BioSpace News Archive

Revolution Medicines, Inc. announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 41st Annual J.P. Morgan Healthcare Conference.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced an agreement with the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, to develop NeoImmuneTech’s main asset NT-I7, for the treatment of Acute Radiation Syndrome.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conference and invited investors to participate by webcast.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. PT in San Francisco, CA.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that its first clinical trial site has been contracted and that first dosing of patients is expected in early 2023.

Apellis Pharmaceuticals, Inc. announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT / 12:00 p.m. ET.

C4 Therapeutics, Inc. announced that the Company will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9th at 10:30 am PST.

Samsung Bioepis Co., Ltd. announced that Health Canada has approved HADLIMA™ - a citrate-free, high concentration formulation of biosimilar referencing HUMIRA®.

Alphalyse has performed the world’s first GMP-certified mass spectrometry (MS)-based Host Cell Protein (HCP) analysis for product release testing for Phase 3 clinical trial, after being certified by the Danish Health and Medicines Authority to perform quality control of biological API using MS-based HCP analysis under GMP.

Ascendis Pharma A/S announced that the Company is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference.